AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.
Company Details
- Employees
- 41
- Founded
- -
- Address
- Bundang-Gu, Dongpangyo-Ro, 56, Seongnam-Si,gyeonggi-Do 13535,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aribiousa.com
- HQ
- Seongnam-si, Gyeonggi-do
Aribio Questions
Aribio's website is aribiousa.com
Aribio's LinkedIn profile is https://www.linkedin.com/company/aribio-official
Aribio has
41 employees.
View email and phone details for 41
employees at Aribio.
Aribio's industry is
Biotechnology Research
Aribio's top competitors are
Bridge Biotherapeutics, Inc.,
Janux Therapeutics,
Bridgebio,
Gilead Sciences,
Ionis Pharmaceuticals, Inc.,
Acino,
Avidity Biosciences, Inc.,
Neurocrine Biosciences,
Arcera,
Crinetics Pharmaceuticals.
Aribio's categories are Biotechnology Research
Aribio's founding year is 2010
